Skip to main content
. 2024 Feb 1;19(2):e0293264. doi: 10.1371/journal.pone.0293264

Table 2. Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

Input Unadjusted input Adjusted for 1st year daratumumab (2015) Adjusted for 1st year pembrolizumab (2014)
Costs associated with R&D
Base-case $4,461,200,000 [17] €3,795,249,282 €3,165,890,999
Scenario 1 Cost R&D (CI) $3,114,000,000 [17] €2,649,154,098 €2,209,850,393
Scenario 2 Cost R&D (CI) $6,001,300,000 [17] €5,105,449,097 €4,258,823,109
Scenario 3 Cost R&D (uncapitalized) $1,032,000,000 [17] €877,947,023 €732,358,897
Cost associated with each new indication
Base-case $300,000,000 [18] €267,020,244 €222,740,834
Scenario 4 based on AIM method $446,120,000 [33] €379,524,928 €316,589,100
Cost of product manufacturing (per gram)
Base-case $51 [24] €42.61 €35.55
Scenario 5 cost manufacturing (low) $26 [25] €25.89 €21.59
Scenario 6 cost manufacturing (high) $134 [25] €133.43 €111.30
Profit margin in %
Base-case 20 [9] 20 20
Scenario 7 profit margin 0% 0 0 0
Scenario 8 highest profit margin 76.5 [34] 76.5 76.5
Patent period
Scenario 9 patent period 2035 & 2036[22] 2035 2036
Type of cost-based price model
Scenario 10 indication-based pricing (IBP) IBP IBP IBP